Construction of a chiral central nervous system (CNS)-active aminotetralin drug compound based on a synthesis strategy using multitasking properties of (s)-1-phenylethylamine

Accounts of Chemical Research

Volumn 40, Issue 12, 2007, Pages 1377-1384

  Federsel, Hans Jürgen ^a   Hedberg, Martin ^b   Qvarnström, Fredrik R ^b   Sjögren, Magnus P T ^b   Tian, W E I ^b  

^a AstraZeneca   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38049049180     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar700102c     Document Type: Review

References (31)

1. 1B receptor antagonist AR-A000002 to guniea pigs. Psychopharmacology 2004, 172, 333-340.
2. 1B autoreceptor antagonist. Eur. J. Pharmacol. 2004, 499, 67-75.
3. 1B receptor antagonist, AR-A000002. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369, 330-337.
4. Stirling, D. I.; Zeitlin, A. L.; Matcham, G. W. Enantiomeric enrichment and stereoselective synthesis of chiral amines. U.S. Patent 4,950,606, 1990.
5. 1B/D receptors in psychiatric disorders and their potential as target for therapy. Eur. J. Pharmacol. 2000, 404, 1-12.
6. (b) Jones, B. J.; Blackburn, T. P. The medical benefit of 5-HT research. Pharmacol., Biochem. Behav. 2002, 71, 555-568.
7. 1B receptors: From protein to physiological function and behavior. Neurosci. Biobehav. Rev. 2004, 28, 565-582.
8. Federsel, H.-J. Logistics of process R&D: Transforming laboratory methods to manufacturing scale. Nat. Rev. Drug Discovery 2003, 2, 654-664.
9. Celgene Corp., P.O. Box 4914, 7 Powder Horn Drive, Warren, NJ 07059. The company name has now changed to Chiragene.
10. Berg, S.; Linderberg, M.; Ross, S.; Thorberg, S.-O.; Ulff, B. Preparation of 1,2,3,4-tetrahydronaphthalenes as h5-HT1B antagonists. PCT Int. Appl. WO 9,905,134, 1999.
11. Rajšner, M.; Svátek, E.; Metyšová, J.; Bartošová, M.; Mikšík, F.; Protiva, M. Fluorinated tricyclic neuroleptics with prolonged effects; some new 8-chloro-3-fluoro-10- piperazino-10,11-dihydrodibenzo[b, f]thiepins. Collect. Czech. Chem. Commun. 1977, 42, 3079-3093.
12. Lewis, E. E.; Elderfield, R. C. 3,5-Dimethyl-, 2-ethyl-5-methyl-, and 3-ethyl-5-methyl-phenantrene. A contribution to the abnormal selenium dehydrogenation of strophanthidin. J. Org. Chem. 1940, 5, 290-299.
13. (a) Sims, J. J.; Selman, L. H.; Cadogan, M. 6-Methoxy-β-tetralone. Org. Synth. 1971, 51, 109-112.
14. (b) Hunden, D.C. An improved synthesis of β-tetralone. Org. Prep. Proc. Int. 1984, 16, 294-297.
15. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 1996, 61, 3849-3862.
16. Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Analysis of the reactions used for the preparation of drug candidate molecules. Org. Biomol. Chem. 2006, 4, 2337-2347.
17. (a) Old, D. W.; Wolfe, J. P.; Buchwald, S. L. A highly active catalyst for palladium-catalyzed cross-coupling reactions: Room-temperature Suzuki couplings and amination of unactivated aryl chlorides. J. Am. Chem. Soc. 1998, 120, 9722-9723.
18. (b) Hartwig, J. F.; Kawatsura, M.; Hauck, S. I.; Shaughnessy, K. H.; Alcazar-Roman, L. M. Room-temperature palladium-catalyzed amination of aryl bromides and chlorides and extended scope of aromatic C-N bond formation with a commercial ligand. J. Org. Chem. 1999, 64, 5575-5580.
19. (c) Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides. J. Org. Chem. 2000, 65, 1144-1157.
20. (d) Mayssam, H. A.; Buchwald, S. L. An improved method for the palladium-catalyzed amination of aryl iodides. J. Org. Chem. 2001, 66, 2560-2565.
21. (e) Jiang, L.; Buchwald, S. L. Palladium-catalyzed aromatic carbon-nitrogen bond formation. In Metal-Catalyzed Cross-Coupling Reactions; de Meijere, A., Diederich, F., Eds.; Wiley-VCH: Weinheim, Germany, 2004; Vol. 2, Chapter 13, pp 699-760.
22. For an authoritative reassessment of mechanistic aspects of the Buchwald-Hartwig reaction, see (f) Shekhar, S.; Ryberg, P.; Hartwig, J. F.; Mathew, J. S.; Blackmond, D. G.; Strieter, E. R.; Buchwald, S. L. Re-evaluation of the mechanism of the amination of aryl halides catalyzed by BINAP-ligated palladium complexes. J. Am. Chem. Soc. 2006, 128, 3584-3591.
23. (a) Tschaen, D. M.; Abramson, L.; Cai, D.; Desmond, R.; Dolling, U.-H.; Frey, L.; Karady, S.; Shi, Y.-J.; Verhoeven, T.R. Asymmetric synthesis of MK-0499. J. Org. Chem 1995, 60, 4324-4330.
24. (b) An extension of this approach into ene carbamates has been reported, albeit with only moderate enantiomeric excess (ee's) (≤77%) being achieved: Dupau, P.; Hay, A.-E.; Bruneau, C.; Dixneuf, P. H. Synthesis of optically active 2-aminotetralin derivatives via enantioselective ruthenium-catalyzed hydrogenation of ene carbamates. Tetrahedron: Asymmetry 2001, 12, 863-867.
25. Kanai, Y.; Saitou, K.; Koki, U. Preparation of optically active primary amine by reduction of imine. Japan Kokai Koho 10,072,411, 1998.
26. 1A receptor as possible anxiolytics and antidepressants. J. Med. Chem. 1993, 36, 2066-2074.
27. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd ed.; Wiley and Sons: New York, 1999; pp 579-580.
28. Product code used by the producer Johnson Matthey, Orchard Road, Royston, Hertfordshire SG8 5HE, U.K. Homepage address: www.jmcatalysts.com/pct.
29. Tian, W. A new process for the synthesis of morpholinylbenzenes. WO 01/87865, 2001.
30. (a) Federsel, H.-J. Stereoselective synthesis of drugs - An industrial perspective. In Chirality in Drug Research; Francotte, E., Lindner, W., Eds.; Wiley-VCH: Weinheim, Germany, 2006; Vol. 33, Chapter 2, pp 29-65.
31. (b) Federsel, H.-J. Chiral drug discovery and development - From concept stage to market launch. In Comprehensive Medicinal Chemistry II; Taylor, J. B., Triggle, D. J., Eds.; Elsevier: Oxford, U.K., 2007; Vol. 2, pp 713-736.